Beranda › Kanker (semua jenis) › Indiana › Indianapolis
Uji klinis Kanker (semua jenis) di Indianapolis, IN
24 studi untuk Kanker (semua jenis) mencari peserta di lokasi sekitar Indianapolis (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Daily Hand-Held Vibration Therapy
Menerima peserta
- Indiana University Melvin & Bren Simon Cancer Center, Indianapolis
- IU Health Joe & Shelly Schwarz Cancer Center, Indianapolis
- Indiana University Health West, Avon · 13 mi jauhnya
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Menerima pesertaStudi observasional
- Indiana University, Indianapolis
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Menerima pesertaFase 3
- Franciscan Health Oncology and Hematology Specialists, Indianapolis
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Menerima pesertaFase 3
- Franciscan St. Francis Health /ID# 279788, Indianapolis
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Menerima pesertaFase 2
- Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- Community Health Network, Indianapolis
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Menerima pesertaFase 2/3
- IN Univ Simon Cancer Center, Indianapolis
- Franciscan Health Indianapolis, Indianapolis
Collection of Tissue Samples for Cancer Research
Menerima pesertaStudi observasional
- Indiana University - Purdue, Indianapolis
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Menerima pesertaFase 3
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
- Community Cancer Center North, Indianapolis
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Menerima pesertaFase 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Project: Every Child for Younger Patients With Cancer
Menerima pesertaStudi observasional
- Riley Hospital for Children, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Menerima pesertaFase 3
- Franciscan Health, Indianapolis
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Menerima pesertaFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
- dan 1 lainnya
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 1
- Franciscan St. Francis Health /ID# 280928, Indianapolis
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Menerima pesertaFase 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
Menerima pesertaSukarelawan sehat diterima
- Indiana University School of Medicine, Indianapolis
Childhood Cancer Survivor Study
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Indiana University/Riley Hospital for Children, Indianapolis
Galleri® in the Medicare Population.
Menerima pesertaSukarelawan sehat diterima
- Community Health Network East, Indianapolis
- Community Health Network South, Indianapolis
The Food Environment, Microbial Cysteine Metabolism, and Cancer Disparities
Menerima peserta
- University Hospital Clinical Research Center, Indianapolis
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Menerima peserta
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
GEMINI-NSCLC: NSCLC Biomarker Study
Menerima pesertaStudi observasional
- Community Health Network, Indianapolis
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- IU Simon Comprehensive Cancer Center, Indianapolis
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Menerima pesertaFase 1/2
- Community Health Network, Inc., Indianapolis
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Menerima peserta
- Indiana University - Melvin and Bren Simon Cancer Center, Indianapolis
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Franciscan Health Indianapolis, Indianapolis
Uji klinis Kanker (semua jenis) di kota lain
- Houston, TX121 studi
- New York City, NY109 studi
- Boston, MA85 studi
- Los Angeles, CA74 studi
- Nashville, TN65 studi
- Philadelphia, PA59 studi
- Washington, DC58 studi
- Durham, NC58 studi
- Chicago, IL51 studi
- Atlanta, GA49 studi
- Seattle, WA49 studi
- Arlington, VA48 studi
Studi lain di Indianapolis
- Kanker Paru Non-Sel Kecil32 studi
- Gagal Jantung23 studi
- Obesitas20 studi
- Kanker Payudara20 studi
- Kanker Metastatik19 studi
- Kanker Kolorektal18 studi
- Kanker Ovarium17 studi
- Penyakit Kardiovaskular17 studi
- Kanker Paru16 studi
- Diabetes Tipe 114 studi
- Kanker Endometrium14 studi
- Penyakit Alzheimer14 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.